Sarepta Therapeutics (SRPT) Continues Run as Eteplirsen Sentiment Remains High
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/10/2026
- Wall Street posts weekly gains with earnings, inflation data on tap
- Oil prices settle higher as more production shut ahead of hurricane
- Apple cuts iPhone 18 Pro orders due to soft demand, Nikkei Asia reports
- UBS flags level in gold prices where dip buyers will likely emerge
- Telecom stocks tumble on SpaceX spectrum acquisition news
Tweet
Share
E-mailGet Alerts SRPT Hot Sheet
Join SI Premium – FREE
Sarepta Therapeutics (Nasdaq: SRPT) shares are higher again on the session Friday, following a 14.3 percent gain on Thursday.
Shares have been strong since positive reports hit on August 15th for its DMD treatment, Eteplirsen.
Sentiment continued yesterday from this article.
Shares are up 13 of the last 16 sessions, or 14 of 17 if Sarepta closes higher Friday.
Shares have been strong since positive reports hit on August 15th for its DMD treatment, Eteplirsen.
Sentiment continued yesterday from this article.
Shares are up 13 of the last 16 sessions, or 14 of 17 if Sarepta closes higher Friday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sarepta Therapeutics (SRPT) PT Lowered to $17 at RBC Capital
- Seagate Falls 9%, Western Digital Down 6%
- Lumentum's optical components sold out through early 2029: CEO
Create E-mail Alert Related Categories
Insiders' Blog, Momentum MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
